Ten years of improvement innovation in cystic fibrosis care.
Stevens DP, Marshall BC. BMJ Quality and Safety. 2014; 23(1)


Cystic Fibrosis Foundation and European Cystic Fibrosis Society Survey of cystic fibrosis mental health care delivery.
Abbott J, Elborn JS, Georgiopoulos AM, Goldbeck L, Marshall BC, Sabadosa KA, Smith BA, Quittner AL. J Cyst Fibros 2015

Cystic Fibrosis Foundation Pulmonary Guideline: Pharmacologic Approaches to Prevention and Eradication of Initial Pseudomonas aeruginosa Infection.
Mogayzel PJ, Naureckas ET, Robinson KA, Brady C, Guill M, Lahiri T, Lubsch L, Matsui J, Oermann C, Ratjen F, Rosenfeld M, Simon R, Hazel L, Sabadosa K, Marshall BC, and the Cystic Fibrosis Foundation Pulmonary Clinical Practice Guidelines Committee. Ann Am Thorac Soc 2014;11(10):1640-50

Longevity of Patients with Cystic Fibrosis in 2000 to 2010 and beyond: survival analysis of the cystic fibrosis foundation patient registry.
MacKenzie T, Gifford AH, Sabadosa KA, Quinton HB, Knapp EA, Goss CH Marshall BC. Ann Intern Med 2014;161(4):233-41

Infection Prevention and Control Guideline for Cystic Fibrosis: 2013 Update
Lisa Saiman; Jane D. Siegel; John J. LiPuma; Rebekah F. Brown; Elizabeth A. Bryson; Mary Jo Chambers; Veronica S. Downer; Jill Fliege; Leslie A. Hazle; Manu Jain; Bruce C. Marshall; Catherine O’Malley; Suzanne R. Pattee; Gail Potter-Bynoe; Siobhan Reid; Karen A. Robinson; Kathryn A. Sabadosa; H. Joel Schmidt; Elizabeth Tullis; Jennifer Webber; David J. Weber. Infect Control Hosp Epidemiol. 2014; 35(S1):S1-S67

Rebuttal from Dr. Jain et al.
Jain M, Saiman LM, Sabadosa K, LiPuma JJ. Chest 2014; 145(4):683-4

Point: does the risk of cross infection warrant exclusion of adults with cystic fibrosis from cystic fibrosis foundation events? Yes.
Jain M, Saiman LM, Sabadosa K, LiPuma JJ. Chest 2014. 145(4):678-80

Highly effective cystic fibrosis clinical research teams: critical success factors.
Retsch-Bogart GZ, Van Dalfsen JM, Marshall BC, George C, Pilewski JM, Nelson EC, Goss CH, Ramsey BW. J Gen Intern Med. 2014;29(S3);S714-23

Development and validation of a cystic fibrosis patient and family member experience of care survey.
Homa K, Sabadosa KA, Nelson EC, Rogers WH, Marshall BC. Qual Manag Health Care. 2013; 22(2):100-16

Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health.
Mogayzel PJ Jr. Naureckas ET, Robinson Ka, Mueller G, Hadjiliadis D, Hoag JB, Lubsch L, Hazle L, Sabadosa K, Marshall B, Pulmonary Clinical Practice Guidelines Committee. Am J Respir Crit Care Med 2013; 187(7):680-9

Better nutritional status in early childhood is associated with improved clinical outcomes and survival in patients with cystic fibrosis.
Yen EH, Quinton H, Borowitz D. J Pediatr. 2013; 162(3):530-535.

An update on the screening, diagnosis, management, and treatment of vitamin D deficiency in individuals with cystic fibrosis: evidence-based recommendations from the Cystic Fibrosis Foundation.
Tangpricha V, Kelly A, Stephenson A, Maguiness K, Enders J, Robinson KA, Marshall BC, Borowitz D, Cystic Fibrosis Foundation Vitamin D Evidence-Based Review Committee. J Clin Endocrinol Metab. 2012;97(4):1082-93

Validation and use of a parametric model for projecting cystic fibrosis survivorship beyond observed data: A birth cohort analysis.
Jackson AD, Daly L, Jackson AL, Kelleher C, Marshall BC, Quinton HB, Fletcher G, Harrington M, Zhou S, McKone EF, Gallagher C, Foley L, Fitzpatrick P. Thorax. 2011;66:674-679

The application of current lifetable methods to compare cystic fibrosis median survival internationally is limited.
Jackson AD, Daly L, Kelleher C, Marshall BC, Quinton HB, Foley L, Fitzpatrick P. J Cyst Fibros. 2011;10:62-65

Clinical care guidelines for cystic fibrosis-related diabetes: A position statement of the American diabetes association and a clinical practice guideline of the cystic fibrosis foundation, endorsed by the pediatric endocrine society.
Moran A, Brunzell C, Cohen RC, Katz M, Marshall BC, Onady G, Robinson KA, Sabadosa KA, Stecenko A, Slovis B, Committee CG. Diabetes Care. 2010;33:2697-2708

Epidemiology, pathophysiology, and prognostic implications of cystic fibrosis-related diabetes: a technical review.
Moran A,  Becker D, Casella SJ, Gottlieb PA, Kirkman MS, Marshall BC, Slovis B; CFRD Consensus Conference Committee. Diabetes Care. 2010. 33(12):2677-83.

Cystic fibrosis pulmonary guidelines: pulmonary complications: hemoptysis and pneumothorax.
Flume PA, Mogayzel PJ Jr, Robinson KA, Rosenblatt RL, Quittell L, Marshall BC, Clinical Practice Guidelines for Pulmonary Therapies Committee; Cystic Fibrosis Foundation Pulmonary Therapies Committee. Am J Respir Crit Care Med. 2010; 182(3):298-306

Cystic Fibrosis pulmonary guidelines: Treatment of pulmonary exacerbations.
Flume PA, Mogayzel PJ Jr, Robinson KA, Coss CH, Rosemblatt RL, Kuhn RJ, Marshall BC, Clinical practice guidelines for pulmonary therapies committee. Am J Respir Crit Care Med. 2009;108(9):802-8

Cystic fibrosis pulmonary guidelines: airway clearance therapies.
Flume PA, Robinson KA, O’Sullivan BP, Finder JD, Vender RL, Willey-Courand DB, White TB, Marshall BC; Clinical practice guidelines for pulmonary therapies committee. Respir Care. 2009;54(4):522-37

Cystic fibrosis foundation evidence-based guidelines for management of infants with cystic fibrosis.
Cystic Fibrosis F, Borowitz D, Robinson KA, Rosenfeld M, Davis SD, Sabadosa KA, Spear SL, Michel SH, Parad RB, White TB, Farrell PM, Marshall BC, Accurso FJ. J Pediatr. 2009;155:S73-93

Cystic fibrosis foundation practice guidelines for the management of infants with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome during the first two years of life and beyond.
Cystic Fibrosis F, Borowitz D, Parad RB, Sharp JK, Sabadosa KA, Robinson KA, Rock MJ, Farrell PM, Sontag MK, Rosenfeld M, Davis SD, Marshall BC, Accurso FJ. J Pediatr. 2009;155:S106-116

Respiratory microbiology of patients with cystic fibrosis in the united states, 1995 to 2005.
Razvi S, Quittell L, Sewall A, Quinton H, Marshall B, Saiman L. Chest. 2009;136:1554-1560

Bacterial contamination of cystic fibrosis clinics.
Zuckerman JB, Zuaro DE, Prato BS, Ruoff KL, Sawicki RW, Quinton HB, Saiman L, Infection Control Study Group. J Cyst Fibros. 2009;8:186-192

Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: Results of a systematic review.
Stallings VA, Stark LJ, Robinson KA, Feranchak AP, Quinton H, Clinical Practice Guidelines on G, Nutrition S, Ad Hoc Working G. J Am Diet Assoc. 2008;108:832-839

Cystic fibrosis pulmonary guidelines: Chronic medications for maintenance of lung health.
Flume PA, O'Sullivan BP, Robinson KA, Goss CH, Mogayzel PJ, Jr., Willey-Courand DB, Bujan J, Finder J, Lester M, Quittell L, Rosenblatt R, Vender RL, Hazle L, Sabadosa K, Marshall B, Cystic Fibrosis Foundation PTC. Am J Respir Crit Care Med. 2007;176:957-969

Current issues in quality improvement in cystic fibrosis.
Quinton HB, O'Connor GT. Clin Chest Med. 2007;28:459-472

Median household income and mortality rate in cystic fibrosis.
O'Connor GT, Quinton HB, Kneeland T, Kahn R, Lever T, Maddock J, Robichaud P, Detzer M, Swartz DR. Pediatrics. 2003;111:e333-339

Risk factors for initial acquisition of pseudomonas aeruginosa in children with cystic fibrosis identified by newborn screening.
Maselli JH, Sontag MK, Norris JM, MacKenzie T, Wagener JS, Accurso FJ. Pediatr Pulmonol. 2003;35:257-262

Case-mix adjustment for evaluation of mortality in cystic fibrosis.
O'Connor GT, Quinton HB, Kahn R, Robichaud P, Maddock J, Lever T, Detzer M, Brooks JG, Northern New England Cystic Fibrosis C. Pediatr Pulmonol. 2002;33:99-105

knowledge informs change